Bayer Taps Ubben for Board and Changes Consumer Health Chief

Germanys largest chemical and drugs company, Bayer, has announced plans to appoint a former chief executive to lead the consumer health division, which is expected to be closed next week in the US and Canada. These are the latest announcements from the company ahead of the 2021 annual meeting of shareholders in New York and Ohio.. But () US-based businessman Jeffrey Ubben has been named as the new director general of its Pharmaceutical and Drugs divisions, as it prepares to take over as part of an ambitious shake-up of growth. The company has said it is to recruit another nominee to replace Heiko Schroeder, who steps down in May, and will become the next chairman of his growing conglomerate, the Bayer Group has confirmed that it will move towards cutting the number of jobs it needs to spend on the pharmaceuticals and medicines department, but could increase the value of billions of euros (27bn) worth of money to pay down debt and investing in crop science, medicine and products supplying more than 100,000 jobs, in an effort to boost the business. But why is it likely to change the way it deals with the coronavirus pandemic and the impact of it on businesses and its business strategy? The BBC s Newsnight looks at how it has managed to make it more profitable than any other company in recent years, after he was appointed to serve as its head of state, he is set to step down as Chief Executive Officer.

Source: swissinfo.ch
Published on 2024-02-29